statistiche ricercatore

Continente	#
EU - Europa	783
NA - Nord America	486
AS - Asia	297
SA - Sud America	101
AF - Africa	6
Continente sconosciuto - Info sul continente non disponibili	2
Totale	1.675

Nazione	#
US - Stati Uniti d'America	472
RU - Federazione Russa	408
SG - Singapore	133
BR - Brasile	86
IT - Italia	86
IE - Irlanda	80
SE - Svezia	73
CN - Cina	55
DE - Germania	33
HK - Hong Kong	29
VN - Vietnam	25
PL - Polonia	21
FI - Finlandia	13
JP - Giappone	13
AT - Austria	12
FR - Francia	12
IN - India	10
GB - Regno Unito	9
BE - Belgio	8
BD - Bangladesh	6
CA - Canada	6
ES - Italia	5
MX - Messico	5
ID - Indonesia	4
IQ - Iraq	4
PE - Perù	4
VE - Venezuela	4
CZ - Repubblica Ceca	3
LT - Lituania	3
NL - Olanda	3
UA - Ucraina	3
AR - Argentina	2
BY - Bielorussia	2
DO - Repubblica Dominicana	2
EC - Ecuador	2
HU - Ungheria	2
IR - Iran	2
MA - Marocco	2
PH - Filippine	2
PK - Pakistan	2
PT - Portogallo	2
SA - Arabia Saudita	2
TR - Turchia	2
AE - Emirati Arabi Uniti	1
BG - Bulgaria	1
BO - Bolivia	1
CH - Svizzera	1
CO - Colombia	1
EE - Estonia	1
EG - Egitto	1
EU - Europa	1
GE - Georgia	1
GR - Grecia	1
IL - Israele	1
KZ - Kazakistan	1
MK - Macedonia	1
MY - Malesia	1
PS - Palestinian Territory	1
PY - Paraguay	1
TG - Togo	1
TH - Thailandia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UZ - Uzbekistan	1
XK - ???statistics.table.value.countryCode.XK???	1
ZA - Sudafrica	1
Totale	1.675

Nome	#
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience	199
PRRT Retreatments: Renal Function Evaluation	197
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy	193
BRAFV600Emutation is associated with increased prevalence of contralateral lymph-node metastases in low and low-to-intermediate risk papillary thyroid cancer	178
Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients	175
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience	166
BRAF and RAS mutations in differentiated thyroid cancer of patients with low-risk to intermediate-risk treated with radioiodine therapy	148
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients	145
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome	109
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature	102
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature	96
Totale	1.708

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	12	0	0	0	0	0	0	0	0	0	4	5	3
2021/2022	92	2	4	2	8	4	3	1	3	2	9	9	45
2022/2023	280	23	37	14	22	25	35	7	19	90	3	5	0
2023/2024	60	5	4	6	3	6	18	1	0	0	5	4	8
2024/2025	333	8	10	10	12	22	11	21	64	69	22	43	41
2025/2026	858	67	49	49	40	59	205	101	133	111	44	0	0
Totale													1.708